BeOne Medicines

A global oncology company that is discovering and developing innovative treatments for patients worldwide. Cancer has no borders. Neither do we.

[BeOne Medicines @BeOneMedicines]

¡Hola, Madrid! Just 1 day to go until #ESMO26. We look forward to spotlighting the momentum across our solid tumor pipeline and raising expectations where progress has been limited. Visit us at booth #8026, Hall 8.

Discover how we’re working to change the game in solid tumor oncology: https://t.co/NCCq0eubYO

#TeamBeOne #BeOneAgainstCancer

[BeOne Medicines @BeOneMedicines]

Cancer treatment has transformed. But progress in hepatocellular carcinoma (HCC) has been harder to achieve.

At BeOne, we believe changing the outlook starts with understanding what makes HCC different and pursuing science designed around the disease.

As new evidence emerges at #ESMO2026, we explore what it could take to move progress forward for patients.

Read more: https://t.co/bS4iMa1SBH

#BeOneAgainstCancer #LiverCancer

[BeOne Medical Affairs @BeOneMedAffairs]

At #ESMO26, BeOne-supported research will explore a range of scientific topics across oncology, including novel therapeutic modalities, biomarker-driven approaches, early clinical development, and outcomes in specific patient populations.

Learn more about our scientific program on BeOne Medical: https://t.co/faWBXn1avT

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: The European Commission has granted our GPC3x4-1BB bispecific antibody Orphan Drug Designation for the treatment of hepatocellular carcinoma (HCC).

#LiverCancer #HCC #BeOneInnovator

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: At #ESMO26, we’re presenting 11 abstracts, including 9 posters and 2 oral presentations, highlighting the rapid advancement of our oncology pipeline.

We’re working to change the game in solid tumor oncology, with proof-of-concept assets advancing across our strategically focused disease areas.

Explore the data here: https://t.co/WGVRFcneaN

#BeOneInnovator

[BeOne Medicines @BeOneMedicines]

The treatment landscape for chronic lymphocytic leukemia (CLL) has shifted in fundamental ways, and the opportunity now is to keep that progress moving forward.

At BeOne, we’re committed to building evidence that is deep and broad enough to support confident treatment decisions across the full range of patients with CLL.

We’re helping move that progress forward. Read more: https://t.co/TZBVJYlfwG

#CLL #BeOneAgainstCancer

[BeOne Medicines @BeOneMedicines]

Cancer treatments have never held more promise. Why aren’t more patients benefiting from them?

We shared with @USATODAY how chronic lymphocytic leukemia (CLL) highlights the gap between scientific innovation and a healthcare system that has failed to keep pace, and what it will take to help more patients get the right care at the right time.

Read the full article, in partnership with Mediaplanet and hosted by USA TODAY: https://t.co/YerIsMvgvc

[BeOne Medicines @BeOneMedicines]

In chronic lymphocytic leukemia (CLL), a headline result is just the beginning.

At BeOne, we believe what matters is whether the benefit holds over time, and whether the evidence reflects the full spectrum of patients.

In a disease where patients may live with their diagnosis for decades, long-term follow-up shouldn’t be an outlier. It is the evidence standard that should shape frontline treatment decisions.

Learn more about how we’re helping build momentum in CLL treatment: https://t.co/oMiWZZHx6O

#CLL #BeOneAgainstCancer

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: This week, we announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for our PD-1 inhibitor combination therapy for the first-line recurrent or metastatic nasopharyngeal carcinoma.

This milestone marks an important step in the reimbursement pathway, bringing eligible patients one step closer to publicly funded access to our PD-1 inhibitor in Canada.

Read the full announcement: https://t.co/zAsRFfAwRR

#Oncology #BeOneInnovator

[BeOne Medicines @BeOneMedicines]

The latest installment of Expert Answers in HER2+ Gastroesophageal Cancer features Dr. Jaffer Ajani discussing advances in HER2- targeted therapies.

Learn more: https://t.co/A1kS3lMV9o

#GastroesophagealCancer #HER2 #Biomarkers #CancerResearch

[BeOne Medicines @BeOneMedicines]

Scientific progress has transformed what’s possible for people living with chronic lymphocytic leukemia (CLL). But the healthcare system has failed to keep pace with science.

Too many patients still face gaps in biomarker testing, CLL expertise, care coordination, insurance coverage and more that stand between them and the latest advances in CLL care.

That’s why we partnered with @News_CRA and the broader blood cancer community on a first-of-its-kind national assessment of the CLL care ecosystem: When Innovation Outpaces Access: Closing the Gap in CLL Care.

The report outlines five actions to help more patients receive the right treatment at the right time:

✅ Expand access to biomarker testing

✅ Improve access to scientifically accurate information

✅ Connect more patients to CLL expertise

✅ Reduce insurance barriers that delay or deny treatment

✅ Increase transparency and promote responsible AI in cancer care

Learn more and download the full report: https://t.co/6rmIsxWfYe

#BloodCancerAwarenessMonth #CLL

[BeOne Medicines @BeOneMedicines]

Learn about the importance of biomarkers from Dr. Manish Shah in this installment of Expert Answers in HER2+ Gastroesophageal Cancer

https://t.co/mVshv7byE2

#GastroesophagealCancer #HER2 #Biomarkers #CancerResearch

[BeOne Medicines @BeOneMedicines]

The regimen including our PD-1 inhibitor in combination with a HER2-targeting bispecific antibody plus chemotherapy has been included in the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)  for Esophageal and Esophagogastric Junction Cancers and for Gastric Cancer as the only preferred immunotherapy-containing treatment option recommended for patients with first line unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.

NCCN Guidelines play an important role in informing treatment decisions across the oncology ecosystem, making this a significant milestone for patients living with HER2+ GEA, providers, and our company.

Learn more: https://t.co/6OTA2XNC9r

#BeOneAgainstCancer #NCCN

[BeOne Medicines @BeOneMedicines]

Watch this installment of Expert Answers in HER2+ Gastroesophageal Cancer to hear Dr. Yelena Janjigian’s perspective on the evolving treatment landscape.

Learn more: https://t.co/8fRE6flN88

#GastroesophagealCancer #HER2 #Biomarkers #CancerResearch

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: At #WCLC26, we’re sharing new data across four abstracts - 3 posters and 1 oral presentation - featuring new data from our PD-1 inhibitor. With lung cancer remaining the leading cause of cancer death worldwide, we’re proud to contribute to the research and scientific exchange driving the field forward. To find out more, visit us at Booth 812.

#LungCancer #BeOneInnovator

[BeOne Medicines @BeOneMedicines]

We’re in Seoul for #WCLC26, joining the global conversation on lung cancer.

We’re sharing new data, connecting with experts and reinforcing our commitment to innovation in lung cancer - from the science we’re presenting today to the pipeline we’re advancing for the future.

If you’re in Seoul, come visit us at Booth 812.

#LungCancer #BeOneInnovator

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: Today, we announced positive results from a further analysis of our Phase 3 study evaluating a combination regimen including a HER2- targeted bispecific antibody that we have licensed in Asia Pacific (excluding Japan) and chemotherapy with and without our PD-1 inhibitor in patients with HER2+ GEA.

Learn more about today’s news: https://t.co/V6krNCvOMI

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: The U.S. FDA granted approval for our PD-1 inhibitor in combination with a HER2-targeting bispecific antibody plus chemotherapy for the first-line treatment of HER2+ unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA), regardless of PD-L1 status.

Full announcement: https://t.co/7LqJGpFKWI

#BeOneAgainstCancer #GEA #Oncology

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: Together, with the BeOne Care Foundation, we’re renewing our partnership with @themaxfndn to expand access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries. This marks an important stride in our work to eliminate barriers to accessible cancer care.

Learn more: https://t.co/4jrMjZpFUS

#BeOneAgainstCancer

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: We’re announcing a new collaboration with @RevMedicines that leverages the strengths of our companies and shared purpose to advance innovation for patients with difficult-to-treat cancers around the world.

Read the full press release here:  https://t.co/RTbzUcj1T9